India Pharma Outlook Team | Friday, 13 March 2026
Zydus Lifesciences has launched AI-powered CGM devices—Diasens and GlucoLive—to strengthen its digital tools for diabetes management.
The new continuous glucose monitoring (CGM) portfolio uses artificial intelligence to deliver real-time glucose insights and enable remote care through connected health systems.
The devices automatically stream glucose readings to a patient’s smartphone every three minutes without manual scanning. This constant data flow ensures uninterrupted monitoring, including overnight readings and emergency alerts. The AI-powered CGM devices aim to simplify glucose tracking while helping doctors and caregivers respond faster to abnormal readings.
Also Read: Advancing Interventional Radiology in India Through Collaboration
To build a connected care ecosystem, Zydus has partnered with TatvaCare to launch the GoodFlip platform. The app analyzes medical reports using AI and provides personalized guidance on diet and exercise. It also offers digital consultations, lab bookings, and a secure vault to store medical records. Through the app’s clinician dashboard, doctors can monitor patient data remotely and adjust treatment plans based on trends.
Speaking on the launch, Sharvil Patel, Managing Director, Zydus Lifesciences Limited, said, “The launch of Diasens and GlucoLive strengthen our companion diagnostics portfolio for chronic disease management. Focused on patient-centric convenience and better quality of life, these CGMs powered by AI technology, will give patients real-time access to key glycaemic data on their mobile devices, simplifying monitoring and control. The convergence of science, innovation, health and technology is critical for patients managing chronic diseases like diabetes, CKD, or organ transplant – offering a quick, reliable, and safe glucose monitoring solution with utmost convenience.”
India faces a major diabetes burden. According to the ICMR-INDIAB study published in The Lancet Diabetes & Endocrinology, the country has more than 101 million diabetics and 136 million pre-diabetics. Despite this, most glucose monitoring still relies on periodic finger-prick tests or HbA1c checks every few months.
